Embecta (EMBC) said Tuesday it has received the US Food and Drug Administration's 510(k) clearance for disposable patch pump for insulin delivery for the treatment of both type 1 and type 2 diabetes.
The system features a tubeless patch pump with a 300-unit insulin reservoir and a secured controller equipped with Bluetooth technology for a user-friendly interface and experience.
Embecta's said its patch pump development program also includes plans to introduce a closed-loop version featuring an insulin-dosing algorithm in a future FDA submission.
Shares of Embecta were up 2.3% in recent Tuesday trading.
Price: 16.72, Change: +0.38, Percent Change: +2.33
Comments